Trevi Therapeutics, Inc. $TRVI Holdings Lifted by Profund Advisors LLC

Profund Advisors LLC lifted its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 347.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,425 shares of the company’s stock after acquiring an additional 73,319 shares during the quarter. Profund Advisors LLC’s holdings in Trevi Therapeutics were worth $1,352,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its stake in shares of Trevi Therapeutics by 29.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 29,996 shares of the company’s stock worth $433,000 after buying an additional 6,800 shares in the last quarter. Oppenheimer & Co. Inc. increased its holdings in shares of Trevi Therapeutics by 0.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 100,696 shares of the company’s stock valued at $1,442,000 after purchasing an additional 925 shares in the last quarter. Sterling Capital Management LLC raised its stake in Trevi Therapeutics by 848.7% in the 3rd quarter. Sterling Capital Management LLC now owns 3,567 shares of the company’s stock valued at $51,000 after purchasing an additional 3,191 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Trevi Therapeutics by 131.2% in the third quarter. Assenagon Asset Management S.A. now owns 3,527,035 shares of the company’s stock valued at $50,507,000 after purchasing an additional 2,001,721 shares during the period. Finally, First Light Asset Management LLC purchased a new stake in Trevi Therapeutics in the second quarter valued at approximately $39,113,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Insider Activity

In related news, Director Michael Heffernan sold 39,473 shares of Trevi Therapeutics stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $15.09, for a total transaction of $595,647.57. Following the completion of the transaction, the director directly owned 6,351 shares of the company’s stock, valued at $95,836.59. This trade represents a 86.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 15.39% of the stock is owned by company insiders.

Trevi Therapeutics Stock Up 0.5%

Shares of TRVI stock opened at $13.63 on Tuesday. The firm has a market cap of $1.94 billion, a PE ratio of -40.09 and a beta of 0.98. The stock has a 50 day moving average of $14.61 and a 200-day moving average of $14.33. Trevi Therapeutics, Inc. has a 12 month low of $9.82 and a 12 month high of $20.22.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). As a group, equities analysts predict that Trevi Therapeutics, Inc. will post -0.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. HC Wainwright increased their target price on Trevi Therapeutics from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, July 20th. Morgan Stanley reissued an “overweight” rating and set a $23.00 target price on shares of Trevi Therapeutics in a research note on Friday, August 7th. Raymond James Financial restated a “strong-buy” rating and set a $40.00 price objective on shares of Trevi Therapeutics in a research report on Friday, August 7th. Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a report on Friday, September 25th. Finally, B. Riley Financial increased their price target on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $27.08.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for chronic conditions that have limited therapeutic options. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine, an opioid receptor modulator designed to combine kappa-opioid receptor agonism with mu-opioid receptor antagonism.

Trevi is evaluating Haduvio in conditions involving chronic cough and severe itching. Its clinical development programs have included studies in chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, and chronic pruritus associated with systemic sclerosis, an autoimmune connective-tissue disorder.